Tag: NASDAQ:QURE

Finance

Biotech Gainers: Fate Therapeutics Inc (NASDAQ:FATE), ZIOPHARM Oncology (NASDAQ:ZIOP), Uniqure NV (NASDAQ:QURE), Sorrento Therapeutics (NASDAQ:SRNE)

Fate Therapeutics Inc (NASDAQ:FATE) recently issued a statement that it has enrolled it first patient for the second phase of this study. The primary aim of the PUMA study is to assess the efficacy and safety of PROHEMA in a randomized, controlled environment for patients that are under treatment for hematopoietic stem cell or HSC transplantation for hematologic malignancies. Fate Therapeutics Inc (NASDAQ:FATE) stock performance … Continue reading Biotech Gainers: Fate Therapeutics Inc (NASDAQ:FATE), ZIOPHARM Oncology (NASDAQ:ZIOP), Uniqure NV (NASDAQ:QURE), Sorrento Therapeutics (NASDAQ:SRNE)

Colin Pettis
Finance

Trending Tickers : Xcel Energy (NYSE:XEL), ZOOM Technologies (NASDAQ:ZOOM), uniQure (NASDAQ:QURE), Realty Income Corporation (NYSE:O), Interval Leisure (NASDAQ:IILG)

Xcel Energy Inc. (NYSE:XEL) says it plans to significantly increase safety-related investments in its Minnesota natural gas service region. The utility said in a recent regulatory filing that it intends to spend $15 million in 2015 on pipeline safety improvements, about a twofold increase over past levels. In future years, the company envisions even larger safety-related investments, peaking in 2019 at more than $50 million. … Continue reading Trending Tickers : Xcel Energy (NYSE:XEL), ZOOM Technologies (NASDAQ:ZOOM), uniQure (NASDAQ:QURE), Realty Income Corporation (NYSE:O), Interval Leisure (NASDAQ:IILG)

Jayne Crisman
FB Nasdaq FB Facebook
Finance

Biotech decliners: Aldeyra Therapeutics Inc (NASDAQ:ALDX), Uniqure NV (NASDAQ:QURE), Regulus Therapeutics Inc (NASDAQ:RGLS), Genetic Technologies Limited (ADR) (NASDAQ:GENE)

Aldeyra Therapeutics Inc (NASDAQ:ALDX) Director C. Boyd Clarke purchased 12,500 shares of the stock in a transaction dated Wednesday, May 7th. The stock was purchased at an average price of $8.00 per share, with a total value of $100,000.00. Following the acquisition, the director now directly owns 12,500 shares in the company, valued at approximately $100,000. Aldeyra Therapeutics Inc (NASDAQ:ALDX) stock performance was -8.31% in … Continue reading Biotech decliners: Aldeyra Therapeutics Inc (NASDAQ:ALDX), Uniqure NV (NASDAQ:QURE), Regulus Therapeutics Inc (NASDAQ:RGLS), Genetic Technologies Limited (ADR) (NASDAQ:GENE)

Colin Pettis